Literature DB >> 8246959

The Ewing's sarcoma EWS/FLI-1 fusion gene encodes a more potent transcriptional activator and is a more powerful transforming gene than FLI-1.

W A May1, S L Lessnick, B S Braun, M Klemsz, B C Lewis, L B Lunsford, R Hromas, C T Denny.   

Abstract

EWS/FLI-1 is a chimeric protein formed by a tumor-specific 11;22 translocation found in both Ewing's sarcoma and primitive neuroectodermal tumor of childhood. EWS/FLI-1 has been shown to be a potent transforming gene, suggesting that it plays an important role in the genesis of these human tumors. We now demonstrate that EWS/FLI-1 has the characteristics of an aberrant transcription factor. Subcellular fractionation experiments localized the EWS/FLI-1 protein to the nucleus of primitive neuroectodermal tumor cells. EWS/FLI-1 specifically bound in vitro an ets-2 consensus sequence similarly to normal FLI-1. When coupled to a GAL4 DNA-binding domain, the amino-terminal EWS/FLI-1 region was a much more potent transcriptional activator than the corresponding amino-terminal domain of FLI-1. Finally, EWS/FLI-1 efficiently transformed NIH 3T3 cells, but FLI-1 did not. These data suggest that EWS/FLI-1, functioning as a transcription factor, leads to a phenotype dramatically different from that of cells expressing FLI-1. EWS/FLI-1 could disrupt normal growth and differentiation either by more efficiently activating FLI-1 target genes or by inappropriately modulating genes normally not responsive to FLI-1.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8246959      PMCID: PMC364810          DOI: 10.1128/mcb.13.12.7393-7398.1993

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  33 in total

1.  Characterization of SAP-1, a protein recruited by serum response factor to the c-fos serum response element.

Authors:  S Dalton; R Treisman
Journal:  Cell       Date:  1992-02-07       Impact factor: 41.582

2.  Fusion of the nuclear oncoproteins v-Myb and v-Ets is required for the leukemogenicity of E26 virus.

Authors:  T Metz; T Graf
Journal:  Cell       Date:  1991-07-12       Impact factor: 41.582

Review 3.  Oncogenic conversion by regulatory changes in transcription factors.

Authors:  B Lewin
Journal:  Cell       Date:  1991-01-25       Impact factor: 41.582

4.  BCR first exon sequences specifically activate the BCR/ABL tyrosine kinase oncogene of Philadelphia chromosome-positive human leukemias.

Authors:  A J Muller; J C Young; A M Pendergast; M Pondel; N R Landau; D R Littman; O N Witte
Journal:  Mol Cell Biol       Date:  1991-04       Impact factor: 4.272

5.  v-myb and v-ets transform chicken erythroid cells and cooperate both in trans and in cis to induce distinct differentiation phenotypes.

Authors:  T Metz; T Graf
Journal:  Genes Dev       Date:  1991-03       Impact factor: 11.361

6.  Erythroleukemia induction by Friend murine leukemia virus: insertional activation of a new member of the ets gene family, Fli-1, closely linked to c-ets-1.

Authors:  Y Ben-David; E B Giddens; K Letwin; A Bernstein
Journal:  Genes Dev       Date:  1991-06       Impact factor: 11.361

7.  Ets1, when fused to the GAL4 DNA binding domain, efficiently enhances galactose promotor dependent gene expression in yeast.

Authors:  S Seneca; B Punyammalee; M Bailly; J Ghysdael; M Crabeel
Journal:  Oncogene       Date:  1991-03       Impact factor: 9.867

8.  Convergence of Ets- and notch-related structural motifs in a heteromeric DNA binding complex.

Authors:  C C Thompson; T A Brown; S L McKnight
Journal:  Science       Date:  1991-08-16       Impact factor: 47.728

9.  Molecular analysis of acute promyelocytic leukemia breakpoint cluster region on chromosome 17.

Authors:  J Borrow; A D Goddard; D Sheer; E Solomon
Journal:  Science       Date:  1990-09-28       Impact factor: 47.728

10.  DNA binding by c-Ets-1, but not v-Ets, is repressed by an intramolecular mechanism.

Authors:  F Lim; N Kraut; J Framptom; T Graf
Journal:  EMBO J       Date:  1992-02       Impact factor: 11.598

View more
  149 in total

1.  Dual transforming activities of the FUS (TLS)-ERG leukemia fusion protein conferred by two N-terminal domains of FUS (TLS).

Authors:  H Ichikawa; K Shimizu; R Katsu; M Ohki
Journal:  Mol Cell Biol       Date:  1999-11       Impact factor: 4.272

2.  Induction of a secreted protein by the myxoid liposarcoma oncogene.

Authors:  M Kuroda; X Wang; J Sok; Y Yin; P Chung; J W Giannotti; K A Jacobs; L J Fitz; P Murtha-Riel; K J Turner; D Ron
Journal:  Proc Natl Acad Sci U S A       Date:  1999-04-27       Impact factor: 11.205

3.  The MN1-TEL fusion protein, encoded by the translocation (12;22)(p13;q11) in myeloid leukemia, is a transcription factor with transforming activity.

Authors:  A Buijs; L van Rompaey; A C Molijn; J N Davis; A C Vertegaal; M D Potter; C Adams; S van Baal; E C Zwarthoff; M F Roussel; G C Grosveld
Journal:  Mol Cell Biol       Date:  2000-12       Impact factor: 4.272

4.  Male sterility and enhanced radiation sensitivity in TLS(-/-) mice.

Authors:  M Kuroda; J Sok; L Webb; H Baechtold; F Urano; Y Yin; P Chung; D G de Rooij; A Akhmedov; T Ashley; D Ron
Journal:  EMBO J       Date:  2000-02-01       Impact factor: 11.598

Review 5.  Molecular pathogenesis of Ewing sarcoma: new therapeutic and transcriptional targets.

Authors:  Stephen L Lessnick; Marc Ladanyi
Journal:  Annu Rev Pathol       Date:  2011-09-19       Impact factor: 23.472

Review 6.  Oncogenic partnerships: EWS-FLI1 protein interactions initiate key pathways of Ewing's sarcoma.

Authors:  Hayriye V Erkizan; Vladimir N Uversky; Jeffrey A Toretsky
Journal:  Clin Cancer Res       Date:  2010-06-14       Impact factor: 12.531

Review 7.  Pediatric oncology.

Authors:  Andrew M Davidoff
Journal:  Semin Pediatr Surg       Date:  2010-08       Impact factor: 2.754

8.  EWS/FLI is a Master Regulator of Metabolic Reprogramming in Ewing Sarcoma.

Authors:  Jason M Tanner; Claire Bensard; Peng Wei; Nathan M Krah; John C Schell; Jamie Gardiner; Joshua Schiffman; Stephen L Lessnick; Jared Rutter
Journal:  Mol Cancer Res       Date:  2017-07-18       Impact factor: 5.852

9.  RUNX3 facilitates growth of Ewing sarcoma cells.

Authors:  Krista L Bledsoe; Meghan E McGee-Lawrence; Emily T Camilleri; Xiaoke Wang; Scott M Riester; Andre J van Wijnen; Andre M Oliveira; Jennifer J Westendorf
Journal:  J Cell Physiol       Date:  2014-12       Impact factor: 6.384

10.  A novel role for keratin 17 in coordinating oncogenic transformation and cellular adhesion in Ewing sarcoma.

Authors:  Savita Sankar; Jason M Tanner; Russell Bell; Aashi Chaturvedi; R Lor Randall; Mary C Beckerle; Stephen L Lessnick
Journal:  Mol Cell Biol       Date:  2013-09-16       Impact factor: 4.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.